BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang M, Yu F, Chen X, Li P, Wang K. The Underlying Mechanisms of Noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma. Mol Ther Nucleic Acids 2020;21:13-27. [PMID: 32505000 DOI: 10.1016/j.omtn.2020.05.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang T, Cao L, Feng N, Xu B, Dong Y, Wang M. N6-methyladenosine (m6A)-mediated lncRNA DLGAP1-AS1enhances breast canceradriamycin resistance through miR-299-3p/WTAP feedback loop. Bioengineered 2021;12:10935-44. [PMID: 34866525 DOI: 10.1080/21655979.2021.2000198] [Reference Citation Analysis]
2 Kalhori MR, Soleimani M, Arefian E, Alizadeh AM, Mansouri K, Echeverria J. The potential role of miR-1290 in cancer progression, diagnosis, prognosis, and treatment: An oncomiR or onco-suppressor microRNA? J Cell Biochem 2021. [PMID: 34897783 DOI: 10.1002/jcb.30191] [Reference Citation Analysis]
3 Lee J, Hwang JH, Chun H, Woo W, Oh S, Choi J, Kim LK. PLEKHA8P1 Promotes Tumor Progression and Indicates Poor Prognosis of Liver Cancer. Int J Mol Sci 2021;22:7614. [PMID: 34299245 DOI: 10.3390/ijms22147614] [Reference Citation Analysis]
4 Ma YS, Cao YF, Liu JB, Li W, Deng J, Yang XL, Xin R, Shi Y, Zhang DD, Lv ZW, Fu D. The power and the promise of circRNAs for cancer precision medicine with functional diagnostics and prognostic prediction. Carcinogenesis 2021:bgab071. [PMID: 34313732 DOI: 10.1093/carcin/bgab071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wu A, Hu Y, Xu Y, Xu J, Wang X, Cai A, Liu R, Chen L, Wang F. Methyltransferase-Like 3-Mediated m6A Methylation of Hsa_circ_0058493 Accelerates Hepatocellular Carcinoma Progression by Binding to YTH Domain-Containing Protein 1. Front Cell Dev Biol 2021;9:762588. [PMID: 34888309 DOI: 10.3389/fcell.2021.762588] [Reference Citation Analysis]
6 Shi T, Iwama H, Fujita K, Kobara H, Nishiyama N, Fujihara S, Goda Y, Yoneyama H, Morishita A, Tani J, Yamada M, Nakahara M, Takuma K, Masaki T. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. Int J Mol Sci 2021;22:13071. [PMID: 34884875 DOI: 10.3390/ijms222313071] [Reference Citation Analysis]
7 Li Y, Wang R, Zhang S, Xu H, Deng L. LRGCPND: Predicting Associations between ncRNA and Drug Resistance via Linear Residual Graph Convolution. Int J Mol Sci 2021;22:10508. [PMID: 34638849 DOI: 10.3390/ijms221910508] [Reference Citation Analysis]
8 Shu G, Su H, Wang Z, Lai S, Wang Y, Liu X, Dai L, Bi Y, Chen W, Huang W, Zhou Z, He S, Dai H, Tang B. LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3. J Exp Clin Cancer Res 2021;40:45. [PMID: 33499874 DOI: 10.1186/s13046-021-01854-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hu X, Zhu H, Shen Y, Zhang X, He X, Xu X. The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma. Front Oncol 2021;11:696705. [PMID: 34367979 DOI: 10.3389/fonc.2021.696705] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 El-Mahdy HA, Sallam AM, Ismail A, Elkhawaga SY, Elrebehy MA, Doghish AS. miRNAs inspirations in hepatocellular carcinoma: Detrimental and favorable aspects of key performers. Pathol Res Pract 2022;233:153886. [PMID: 35405621 DOI: 10.1016/j.prp.2022.153886] [Reference Citation Analysis]